Coya Therapeutics (COYA) to Release Quarterly Earnings on Thursday

Posted by Danessa Lincoln on May 6th, 2025

Coya Therapeutics (NASDAQ:COYA – Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Coya Therapeutics to post earnings of ($0.44) per share for the quarter.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million. On average, analysts expect Coya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coya Therapeutics Stock Up 0.6 %

Shares of NASDAQ COYA opened at $6.41 on Tuesday. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $10.24. The company has a market cap of $107.21 million, a P/E ratio of -9.86 and a beta of 0.49. The business’s 50 day moving average is $6.19 and its two-hundred day moving average is $6.34.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. D. Boral Capital reiterated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, April 28th.

Get Our Latest Research Report on Coya Therapeutics

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.